03.04.2017 13:47
Calypso Biotech, a Geneva-based spin-off from Merck, announces that it has entered a global licensing and collaboration agreement with EA Pharma. The two will develop CALY-001, a promising novel treatment for indications such as inflammatory bowel disease.Under this agreement, Calypso Biotech will receive an upfront, milestone and royalty payments.